Additionally, pharmacologic RhoA/ROCK inhibition reduced the production of anti-dsDNA antibody levels and the responsiveness of B cells to B-cell activating factor receptor (BAFF/ BAFFR) (33, 38),suggesting a role in the differentiation of autantibody producing B lymphocytes in SLE (39). This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.